AU2001253334A1 - Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents - Google Patents

Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents

Info

Publication number
AU2001253334A1
AU2001253334A1 AU2001253334A AU5333401A AU2001253334A1 AU 2001253334 A1 AU2001253334 A1 AU 2001253334A1 AU 2001253334 A AU2001253334 A AU 2001253334A AU 5333401 A AU5333401 A AU 5333401A AU 2001253334 A1 AU2001253334 A1 AU 2001253334A1
Authority
AU
Australia
Prior art keywords
chemotherapeutic
tumor
microspheres
composition
paclitaxel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253334A
Other languages
English (en)
Inventor
Moshe Flashner-Barak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU2001253334A1 publication Critical patent/AU2001253334A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001253334A 2000-04-10 2001-04-10 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents Abandoned AU2001253334A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19592000P 2000-04-10 2000-04-10
US60195920 2000-04-10
PCT/US2001/011688 WO2001076567A1 (en) 2000-04-10 2001-04-10 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents

Publications (1)

Publication Number Publication Date
AU2001253334A1 true AU2001253334A1 (en) 2001-10-23

Family

ID=22723363

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253334A Abandoned AU2001253334A1 (en) 2000-04-10 2001-04-10 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents

Country Status (19)

Country Link
US (1) US20020041888A1 (cs)
EP (1) EP1274404A1 (cs)
JP (1) JP2004507451A (cs)
KR (1) KR20030008368A (cs)
CN (1) CN1438882A (cs)
AU (1) AU2001253334A1 (cs)
BR (1) BR0110150A (cs)
CA (1) CA2406484A1 (cs)
CZ (1) CZ20023333A3 (cs)
EA (1) EA200201068A1 (cs)
HU (1) HUP0302296A2 (cs)
IL (1) IL152180A0 (cs)
MX (1) MXPA02009984A (cs)
NO (1) NO20024867L (cs)
PL (1) PL366035A1 (cs)
SK (1) SK14452002A3 (cs)
WO (1) WO2001076567A1 (cs)
YU (1) YU77002A (cs)
ZA (1) ZA200208167B (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
WO2003090722A2 (en) * 2002-04-26 2003-11-06 Teva Pharmaceutical Industries, Ltd. Microparticle pharmaceutical compositions for intratumoral delivery
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
US8940311B2 (en) * 2004-10-21 2015-01-27 Tae-Hong Lim In situ controlled release drug delivery system
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA3054535A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
EP1896007B1 (en) 2005-05-04 2014-03-19 Medigene AG Method of administering a cationic liposomal preparation comprising paclitexel
MX2008011978A (es) 2006-03-22 2009-04-22 Medigene Ag Tratamiento del cancer de seno negativo al triple receptor.
EP2552415B1 (en) 2010-03-29 2016-09-07 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
NZ706745A (en) 2010-06-04 2017-01-27 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
CN103429267B (zh) 2011-01-09 2016-05-04 Anp科技公司 疏水分子诱导的支化聚合物集合体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4345588A (en) * 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins

Also Published As

Publication number Publication date
YU77002A (sh) 2005-09-19
EA200201068A1 (ru) 2003-12-25
EP1274404A1 (en) 2003-01-15
CN1438882A (zh) 2003-08-27
MXPA02009984A (es) 2004-09-10
JP2004507451A (ja) 2004-03-11
PL366035A1 (en) 2005-01-24
NO20024867L (no) 2002-12-06
CA2406484A1 (en) 2001-10-18
SK14452002A3 (sk) 2003-07-01
HUP0302296A2 (hu) 2003-10-28
CZ20023333A3 (cs) 2003-06-18
WO2001076567A1 (en) 2001-10-18
IL152180A0 (en) 2003-05-29
US20020041888A1 (en) 2002-04-11
ZA200208167B (en) 2004-02-10
BR0110150A (pt) 2004-04-27
KR20030008368A (ko) 2003-01-25
NO20024867D0 (no) 2002-10-09

Similar Documents

Publication Publication Date Title
Zhang et al. Convection enhanced delivery of cisplatin-loaded brain penetrating nanoparticles cures malignant glioma in rats
Yang et al. Estrone-modified pH-sensitive glycol chitosan nanoparticles for drug delivery in breast cancer
Floyd et al. Drug encapsulated polymeric microspheres for intracranial tumor therapy: a review of the literature
Cha et al. Advances in drug delivery technology for the treatment of glioblastoma multiforme
EP2057987B1 (en) Pharmaceutical composition containing statin-encapsulated nanoparticle
US9415019B2 (en) Nanocapsules with a polymer shell
US20020041888A1 (en) Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
US20090162425A1 (en) Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents
US11413253B2 (en) Nanoparticle delivery systems
EP2328554A1 (en) Encapsulation of lipophilic or amphiphilic therapeutic agents in nano-emulsions
CN108289833B (zh) 用于递送囊封剂的稳定的已组装纳米结构
CN101129375B (zh) 长春瑞滨固体脂质纳米粒与其冻干制剂及制备方法
van der Veen et al. Biodistribution and tumor localization of stealth liposomal tumor necrosis factor‐α in soft tissue sarcoma bearing rats
CA2631243A1 (en) Liposomal compositions
US20240173412A1 (en) Sensitizing cells to proton radiation
Kang et al. Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly (D, L-lactic acid) nanoparticles
Fathi-karkan et al. NPs loaded with zoledronic acid as an advanced tool for cancer therapy
US6569459B2 (en) Method of administration of paclitaxel-plasma protein formulation
CN116473940A (zh) 一种caf靶向的载药脂质纳米粒及其制备方法
Haque et al. Interstitial chemotherapy and polymer-drug delivery
Gastaldi et al. Delivery of Taxanes: Strategies to Develop Efficient Systems Against Brain Cancers
CA2624883A1 (en) Directed therapy